» Articles » PMID: 37735702

Macrophage Activation Syndrome in Juvenile Dermatomyositis: a Case Report and a Comprehensive Review of the Literature

Overview
Publisher Biomed Central
Specialty Pediatrics
Date 2023 Sep 22
PMID 37735702
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Macrophage activation syndrome (MAS) is a severe and life-threatening syndrome associated with autoimmune diseases. The coexistence of MAS and juvenile dermatomyositis (JDM) is not well reported. This report describes a case of JDM with MAS and summarizes the clinical characteristics and prognosis of MAS in patients with JDM.

Case Presentation: The patient was a 15-year-old female with JDM, presenting with heliotrope rash, muscle weakness, increased muscle enzyme, anti-nuclear matrix protein 2 (NXP2) antibody, and muscle biopsy consistent with JDM. The patient developed fever, cytopenia, and hyperferritinemia three months after the first manifestations. Hemophagocytosis was found in the bone marrow. The final diagnosis was JDM combined with MAS. Despite intensive treatment, the patient died of MAS. By reviewing the literature, we found 17 similar cases. Together with the present case, 18 patients were identified, the median age of disease onset was 13.5 years, and male to female ratio was 1.25: 1. Nine out of 16 (56.3%) patients were complicated with interstitial lung disease (ILD). The median time interval between JDM onset and MAS diagnosis was 9 weeks. At the onset of MAS, all (100%) patients had elevated levels of ferritin and serum liver enzymes. Among 18 patients, 14 (77.8%) had fever, 14/17 (82.4%) had cytopenia, 11/11 (100%) had hepatosplenomegaly, and 13/14 (92.9%) had hemophagocytosis. Five (27.8%) patients showed central nervous system (CNS) involvement. The mortality of MAS rate of in patients with JDM was 16.7%, despite various treatment methods.

Conclusion: . The coexistence of JDM and MAS is underestimated with increased mortality. Hepatosplenomegaly and increased serum levels of ferritin in patients with JDM should raise clinical suspicion for MAS.

Citing Articles

Anti-MDA5 Positive Juvenile Dermatomyositis With Macrophage Activation Syndrome: A Case Report.

Mehair A, Harjacek M Cureus. 2025; 16(12):e75137.

PMID: 39759739 PMC: 11700021. DOI: 10.7759/cureus.75137.


Juvenile dermatomyositis with central nervous system involvement: two case reports from a retrospective single-center cohort, with literature review.

Yang L, Guan W, Liu H, Li Y, Gong Y, Lv Q Front Pediatr. 2024; 12:1409950.

PMID: 38873583 PMC: 11169638. DOI: 10.3389/fped.2024.1409950.


Heterogeneity of macrophage activation syndrome and treatment progression.

Dong Y, Wang T, Wu H Front Immunol. 2024; 15:1389710.

PMID: 38736876 PMC: 11082376. DOI: 10.3389/fimmu.2024.1389710.

References
1.
Ding Y, Ge Y . Anti-melanoma differentiation-associated gene 5 antibody-positive dermatomyositis complicated with macrophage activation syndrome. Ther Adv Chronic Dis. 2022; 13:20406223221098128. PMC: 9109495. DOI: 10.1177/20406223221098128. View

2.
Yamashita H, Matsuki Y, Shimizu A, Mochizuki M, Takahashi Y, Kano T . Hemophagocytic lymphohistiocytosis complicated by central nervous system lesions in a patient with dermatomyositis: a case presentation and literature review. Mod Rheumatol. 2012; 23(2):386-92. DOI: 10.1007/s10165-012-0661-6. View

3.
Kobayashi I, Akioka S, Kobayashi N, Iwata N, Takezaki S, Nakaseko H . Clinical practice guidance for juvenile dermatomyositis (JDM) 2018-Update. Mod Rheumatol. 2020; 30(3):411-423. DOI: 10.1080/14397595.2020.1718866. View

4.
Yajima N, Wakabayashi K, Odai T, Isozaki T, Matsunawa M, Miwa Y . Clinical features of hemophagocytic syndrome in patients with dermatomyositis. J Rheumatol. 2008; 35(9):1838-41. View

5.
Sterba G, Rodriguez C, Sifontes S, Vigilanza P . Macrophage activation syndrome due to methotrexate in a 12-year-old boy with dermatomyositis. J Rheumatol. 2004; 31(5):1014-5. View